Next, we conducted a PFS-related analysis for HCC treated with the combination of lenvatinib and PD-1 inhibitor therapy, and univariate results showed tumor number, NLR, PLR, PNI, CRP, and PMI as potential predictors of PFS. This evidence concerns the gene CRP and hepatocellular carcinoma.